Telomir Pharmaceuticals Inc. (Nasdaq: TELO) has announced its participation in the upcoming BIO International Convention 2025 in Boston, Massachusetts, scheduled from June 16-19, 2025. The company plans to engage in BIO One-on-One Partnering™ meetings to explore potential licensing, strategic collaborations, and M&A opportunities. Additionally, Telomir provided updates on its lead candidate, Telomir-1, which is designed to elongate telomeres, regenerate cells, and address key drivers of biological aging. The company is preparing for an Investigational New Drug $(IND.AU)$ submission by the end of the year and anticipates initiating first-in-human clinical trials in the first half of 2026. Telomir also reported preclinical progress in areas such as retinal regeneration, lifespan extension, Type 2 diabetes reversal, and anti-cancer effects. Furthermore, Telomir is launching a rare disease development initiative targeting conditions like Werner's syndrome, Wilson's disease, Progeria, and dysphonia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.